Research Progress in the Traditional Chinese Medicine Treatment of Alzheimer��s Disease and the Blood-Brain Barrier Transporters
ZHANG Ming-yong1, LIU Min2, HONG Zhan-ying1*, CHAI Yi-feng1
1. Department of Pharmaceutical Analysis, School of Pharmacy,Shanghai Key Laboratory for Pharmaceutical (Chinese Materia Medica)Metabolites Research, Second Military Medical University, Shanghai 200433, China; 2.Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Abstract��Alzheimer��s disease (AD)is a central nervous system disorder with memory and cognitive decline as the main clinical manifestation. Some progresses have been made in laboratory research and clinical applications of the traditional Chinese medicine for AD treatment. However, the AD pathology mechanism and the target of the traditional Chinese medicine remain unclear yet. Blood-brain barrier (BBB)plays a critical role to maintain the dynamic balance of the central nervous system. In the pathological process of AD, the BBB impairment and the abnormity of transporters expression have certain effects on the clearance of amyloid beta-peptides and the drug transport across BBB. This review summarizes the research progress on the traditional Chinese medicine treatment of AD and the dysfunction of BBB transporters, thus providing new prevention and treatment strategies for AD.
������, ����, ��սӢ, ���ݷ�. �����ĺ�Ĭ������ҩ���ƺ�Ѫ������ת�˵����ܱ仯�о���չ[J]. �й�ҩѧ��־, 2018, 53(7): 490-495.
ZHANG Ming-yong, LIU Min, HONG Zhan-ying, CHAI Yi-feng. Research Progress in the Traditional Chinese Medicine Treatment of Alzheimer��s Disease and the Blood-Brain Barrier Transporters. Chinese Pharmaceutical Journal, 2018, 53(7): 490-495.
LI H. Clinical research progress in drug treatment of Alzheimer��s disease[J]. Chin J New Drugs(�й���ҩ��־), 2017,26(6):648-655.
[2]
WANG R, FANG F. Research progress of the role of autophagy in Alzheimer��s disease and drug intervention[J]. Chin Pharm J(�й�ҩѧ��־), 2015, 50(5): 381-385.
[3]
SHI X M, RUAN Y Y, ZHANG L, et al. Effects of safflower yellowon inflammation reaction in the cortical of APP / PS1 transgenic mice[J]. Chin Pharm J(�й�ҩѧ��־), 2016, 51(7): 550-553.
[4]
SALCEDO-TELLO P, ORTIZ-MATAMOROS A, ARIAS C. GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration[J]. Int J Alzheimer��s Dis, 2011,2011(12):189728.
[5]
BANK W. The blood brain barrier in Alzheimer��s disease[J]. Can J Neurol Sci, 1986,13(Suppl.4):446.
[6]
MAHRINGER A, FRICKER G. ABC transporters at the blood-brain barrier[J]. Expert Opin Drug Metabol Toxicol, 2016,12(5): 499-508.
[7]
ABUZNAIT A H, KADDOUMI A. Role of ABC transporters in the pathogenesis of Alzheimer��s disease[J]. ACS Chem Neurosci, 2012, 3(11): 820-831.
[8]
MILLER D S, BAUER B, HARTZ A M. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy[J]. Pharm Rev, 2008, 60(2): 196-209.
[9]
KUHNKE D, JEDLITSCHKY G, GRUBE M, et al. MDR1-P-Glycoprotein(ABCB1) mediates transport of Alzheimer��s amyloid-beta peptides--implications for the mechanisms of abeta clearance at the blood-brain barrier[J]. Brain Pathol, 2007, 17(4): 347-353.
[10]
BARTLES A. Blood-brain barrier P-glycoprotein function in neurodegenerative disease[J]. Curr Pharm Design, 2011, 17(26): 2771-2777.
[11]
DEANE R, BELL R, SAGARE A, et al. Clearance of amyloid-�� peptide across the blood-brain barrier: implication for therapies in Alzheimer��s disease[J]. CNS Neurol Disorders-Drug Targets, 2009, 8(1): 16-30.
[12]
ABUZNAIT A H, CAIN C, INGRAM D, et al. Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer��s disease[J]. J Pharm Pharmacol, 2011, 63(8): 1111-1118.
[13]
RAPOSELLI S, DIGIACOMO M, BALSAMO A. P-gp transporter and its role in neurodegenerative diseases[J]. Curr Topics Med Chem, 2009, 9(2): 209-217.
[14]
CIRRITO J R, DEANE R, FAGAN A M, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model[J]. J Clin Invest, 2005, 115(11): 3285-3290.
[15]
ERICKSON M A, BANKS W A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer��s disease[J]. J Cerebral Blood Flow Metabol, 2013, 33(10): 1500-1513.
[16]
CARRANO A, SNKHCHYAN H, KOOIJ G, et al. ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy[J]. Neurobiol Aging, 2014, 35(3): 565-575.
[17]
SILVERBERG G D, MILLER M C, MESSIER A A, et al. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging[J]. J Neuropathol Exp Neurol, 2010, 69(10): 1034-1043.
[18]
VOGELGESANG S, CASCORBI I, SCHROEDER E, et al. Deposition of Alzheimer��s ��-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans[J]. Pharmacogenet Genom, 2002, 12(7): 535-541.
[19]
VAN ASSEMA D M, LUBBERINK M, BAUER M, et al. Blood-brain barrier P-glycoprotein function in Alzheimer��s disease[J]. Brain, 2012, 135(Pt 1): 181-189.
[20]
XIONG H, CALLAGHAN D, JONES A, et al. ABCG2 is upregulated in Alzheimer��s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40)peptides[J]. J Neur, 2009, 29(17): 5463-5475.
[21]
HE P, LI P, HUA Q, et al. Chronic administration of anti-stroke herbal medicine TongLuoJiuNao reduces amyloidogenic processing of amyloid precursor protein in a mouse model of Alzheimer��s disease[J]. PLoS One, 2013, 8(3): e58181.
[22]
HARA H, KATAOKA S, ANAN M, et al. The therapeutic effects of the herbal medicine, Juzen-taiho-to, on amyloid-beta burden in a mouse model of Alzheimer��s disease[J]. J Alzheimer��s Dis, 2010, 20(2): 427-439.
[23]
RAN G, YE W, QINGGE P, et al. Fuzhisan, a Chinese herbal medicine, suppresses beta-secretase gene transcription via upregulation of SIRT1 expression in N2a-APP695 cells[J]. Int J Clin Exp Med, 2015, 8(5): 7231-7240.
[24]
OKAMOTO H, IYO M, UEDA K, et al. Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions[J]. Neuropsych Dis Treat, 2014, 10: 1727-1742.
[25]
WANG Q, LI H, WANG F X, et al. Huannao Yicong Decoction dxtract reduces inflammation and cell apoptosis in abeta1-42-induced Alzheimer��s disease model of rats[J]. Chin J Integr Med, 2017, 23(9): 672-680.
[26]
CAO Y, JIA X, WEI Y, et al. Traditional Chinese medicine Huannao Yicong Decoction extract decreases tau hyperphosphorylation in the brain of Alzheimer��s disease model rats induced by abeta1-42[J]. Evidence-Based Compl Alter Med, 2016,2016(2):6840432.
[27]
TENG J, XU Z, ZHANG J, et al. Effect of Yizhitongxuan decoction on learning and memory ability, G��q/11 expression and Na+K+ -ATP enzyme activity in rat models of Alzheimer��s disease[J]. J Tradit Chin Med(��ҽ��־), 2014, 34(4):470-476.
[28]
XIA Z, PENG W, CHENG S, et al. Naoling decoction restores cognitive function by inhibiting the neuroinflammatory network in a rat model of Alzheimer��s disease[J]. Oncotarget, 2017, 8(26):42648-42663.
[29]
PARK H R, KIM J Y, LEE Y, et al. PMC-12, a traditional herbal medicine, enhances learning memory and hippocampal neurogenesis in mice[J]. Neu Lett, 2016, 617: 254-263.
[30]
WANG J, YE F, CHENG X, et al. The effects of LW-AFC on intestinal microbiome in senescence-accelerated mouse prone 8 strain, a mouse model of Alzheimer��s disease[J]. J Alzheimer��s Dis, 2016, 53(3): 907-919.
[31]
CHENG S, LEBLANC K J, LI L. Triptolide preserves cognitive function and reduces neuropathology in a mouse model of Alzheimer��s disease[J]. PLoS One, 2014, 9(9): e108845.
[32]
ZHANG J S, ZHOU S F, WANG Q, et al. Gastrodin suppresses BACE1 expression under oxidative stress condition via inhibition of the PKR/eIF2alpha pathway in Alzheimer��s disease[J]. Neuroscience, 2016, 325: 1-9.
[33]
HAMIDPOUR R, HAMIDPOUR M, HAMIDPOUR S, et al. Cinnamon from the selection of traditional applications to its novel effects on the inhibition of angiogenesis in cancer cells and prevention of Alzheimer��s disease, and a series of functions such as antioxidant, anticholesterol, antidiabetes, antibacterial, antifungal, nematicidal, acaracidal, and repellent activities[J]. J Tradit Compl Med, 2015, 5(2): 66-70.
[34]
LI Z, LI H, ZHAO C, et al. Protective effect of notoginsenoside R1 on an APP/PS1 mouse model of Alzheimer��s disease by up-regulating insulin degrading enzyme and inhibiting Aβ accumulation[J]. CNS Neurol Disorders-Drug Targets, 2015, 14(3): 360-369.
[35]
HOU Y, ABOUKHATWA M A, LEI D L, et al. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice[J]. Neuropharmacology,2010, 58(6): 911-920.
[36]
XU M, DONG Y, WAN S, et al. Schisantherin B ameliorates abeta1-42-induced cognitive decline via restoration of GLT-1 in a mouse model of Alzheimer��s disease[J]. Physiol Behav, 2016, 167: 265-273.
[37]
HUH E, KIM H G, PARK H, et al. Houttuynia cordata improves cognitive deficits in cholinergic dysfunction Alzheimer��s disease-like models[J]. Biomol Therap, 2014, 22(3): 176-183.
[38]
WANG R. Resveratrol protects spatial learning and memory function against the reduction of SIRT1 expression and CREB phosphorylation induced by A��1-42 in rats[D]. Taiyuan: Shanxi Medical University, 2012.
[39]
WANG J F. The mechanism underlying the therapeutic effect of resveratrol on Alzheimer��s disease in rats[D]. Tangshan: Hebei United University, 2014.
[40]
WANG C Y, ZHENG W, WANG T, et al. Huperzine A activates Wnt/beta-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model[J]. Neuropsychopharmacol Off Public Am College Neuropsychoparmacol, 2011, 36(5): 1073-1089.
[41]
ZHANG Y, PI Z, SONG F, et al. Ginsenosides attenuate d-galactose- and AlCl3-inducedspatial memory impairment by restoring the dysfunction of the neurotransmitter systems in the rat model of Alzheimer��s disease[J]. J Ethnopharmacol, 2016, 194: 188-195.
[42]
LIAN Q W. Study of the effects of grape seed proanthocyanidin on Alzheimer��s disease in vitro and in vivo model[D]. Guangzhou: Guangzhou University of Chinese Medicine, 2015.
[43]
SHI L L, YANG W N, CHEN X L, et al. The protective effects of tanshinone ��a on neurotoxicity induced by ��-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons[J]. Neurochem Int, 2012, 61(2): 227-235.
[44]
FENG H L, LI R C,WANG H, et al. Effect of curcumin on hippocampal IRS-1 and p-IRS-1 expressions in APP/PS1 double transgenic mice[J]. China J Chin Mater Med(�й���ҩ��־), 2013, 38(9): 1290-1294.
[45]
CHEN Y J, ZHENG H Y, HUANG X X, et al. Neuroprotective effects of icariin on brain metabolism, mitochondrial functions, and cognition in triple-transgenic Alzheimer��s disease mice[J]. CNS Neurosci Therapeut, 2016, 22(1): 63-73.
[46]
LIU L L. The protective estrogen-like effect and mechanism of quercetin on hippocampus neurons of rats[D]. Zhangjiakou: Hebei North University, 2015.
[47]
LI X, CUI J, YU Y, et al. Traditional Chinese nootropic medicine Radix Polygalae and its active constituent onjisaponin B reduce beta-amyloid production and improve cognitive impairments[J]. PLoS One, 2016, 11(3): e0151147.
[48]
PARK S J, JUNG J M, LEE H E, et al. The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or abeta(1-42)-induced cognitive dysfunction in mice[J]. J Ethnopharmacol, 2012, 143(2): 611-620.
[49]
MOON M, KIM H G, CHOI J G, et al. 6-Shogaol, an active constituent of ginger, attenuates neuroinflammation and cognitive deficits in animal models of dementia[J]. Biochem Biophy Res Commun, 2014, 449(1): 8-13.
[50]
MAO J, HUANG S, LIU S, et al. A herbal medicine for Alzheimer��s disease and its active constituents promote neural progenitor proliferation[J]. Aging Cell, 2015, 14(5): 784-796.
[51]
ZHANG N, KANG T, XIA Y, et al. Effects of salvianolic acid B on survival, self-renewal and neuronal differentiation of bone marrow derived neural stem cells[J]. Eur J Pharmacol, 2012, 697(1-3): 32-39.
[52]
BRIER M R, GORDON B, FRIDRICHSEN K, et al. Tau and A�� imaging, CSF measures, and cognition in Alzheimer��s disease[J]. Sci Translat Med, 2016, 8(338): 338ra66.
[53]
KOCAHAN S, DOGAN Z. Mechanisms of Alzheimer��s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors[J]. Clin Psychopharm Neurosci, 2017, 15(1):1-8.
[54]
FRIEDLAN R P. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration[J]. J Alzheimer��s Dis, 2015, 45(2): 349-362.
[55]
JI B S, CEN J, LIU L, et al. In vitro and in vivo study of dolichyl phosphate on the efflux activity of P-glycoprotein at the blood-brain barrier[J]. Int J Develop Neurosci,2013, 31(8): 828-835.
[56]
KIM D G, BYNOE M S. A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier[J]. J Clin Invest, 2016, 126(5):1717-1733.
[57]
FAN X, CHAI L, ZHANG H, et al. Borneol depresses P-glycoprotein function by a NF-��B signaling mediated mechanism in a blood brain barrier in vitro model[J]. Int J Mol Sci, 2015, 16(12): 27576-27588.
[58]
YU B, RUAN M, DONG X, et al. The mechanism of the opening of the blood-brain barrier by borneol: a pharmacodynamics and pharmacokinetics combination study[J]. J Ethnopharmacol, 2013,150(3): 1096-1108.
[59]
YU X Y, LIN S G, CHEN X, et al. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer��s disease, across the blood-brain barrier[J]. Current Drug Metab, 2007, 8(4): 365-377.
[60]
LI J, YUE M, ZHOU D, et al. Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of huperzine A in mice[J]. Food Chem Toxicol, 2017,107:68-73.
[61]
MOHAMED L A, QOSA H, KADDOUMI A. Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats[J]. ACS Chem Neurosci, 2015, 6(5): 725-736.
[62]
MOHAMED L A, KELLER J N, KADDOUMI A. Role of P-glycoprotein in mediating rivastigmine effect on amyloid-beta brain load and related pathology in Alzheimer��s disease mouse model[J]. Bio Et Biophy Acta, 2016, 1862(4): 778-787.
[63]
ABUZNAIT A H, QOSA H, BUSNENA B A, et al. Olive-oil-derived oleocanthal enhances beta-amyloid clearance as a potential neuroprotective mechanism against Alzheimer��s disease: in vitro and in vivo studies[J]. ACS Chem Neurosci, 2013, 4(6): 973-982.
[64]
QOSA H, ABUZNAIT A H, HILL R A, et al. Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer��s disease[J]. J Alzheimer��s Dis,2012, 31(1): 151-165.
[65]
SU J, RUAN X C, ZHANG Y H, et al. Effects of morphine and pethidine on the expression of P-glycoprotein in mouse brain microvascular endothelial cells[J]. J Southern Med Univ(�Ϸ�ҽ�ƴ�ѧѧ��), 2010, 30(8): 1824-1826.
[66]
JUMNONGPRAKHON P, SIVASINPRASASN S, GOVITRAPONG P, et al. Activation of melatonin receptor(MT1/2) promotes P-gp transporter in methamphetamine-induced toxicity on primary rat brain microvascular endothelial cells[J]. Toxicol Vitro, 2017, 41: 42-48.
2018, Vol. 53 
